Section of Advanced Endoscopy, Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, Columbus, OH, 43210, USA.
Section of Pancreatic Disorders, Division of Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Surg Endosc. 2017 Nov;31(11):4558-4567. doi: 10.1007/s00464-017-5516-y. Epub 2017 Apr 4.
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis in part due to delayed diagnosis. Even with advances in cross-sectional imaging, small pancreatic malignancies can be missed. We sought to determine the performance of endoscopic ultrasound (EUS) in those without an obvious mass on multi-detector CT scan (MDCT), but with clinical suspicion for pancreatic malignancy.
Multiple databases were systematically searched to identify studies that assessed the diagnostic performance of EUS after negative or inconclusive pancreatic protocol MDCT for detection of pancreatic malignancy when clinically suspected. A total of four studies met the inclusion criteria. The point estimates in each study were compared to the summary pooled estimates of sensitivity and specificity with the aid of forest plots. Funnel plots and Egger's test were employed to evaluate possible publication bias.
EUS-guided fine needle aspiration was performed in all studies. EUS was performed in 206 subjects with a clinical suspicion of a pancreatic mass but with an indeterminate MDCT. A pancreatic mass (mean size 21 ± 1.2 mm) was identified in 70% (n = 144) of the subjects, and 42.2% (n = 87) were diagnosed with PDAC. The pooled estimates of EUS for diagnosing pancreatic malignancy in the setting of an indeterminate MDCT were a sensitivity of 85% (95% CI 69-94%), specificity of 58% (95% CI 40-74%), positive predictive value of 77% (69-84%), negative predictive value of 66% (95% CI 53-77%), and an accuracy of 75% (95% CI 67-82). The summary area under the ROC curve was 0.80 (95% CI 0.52-0.89). The funnel plots and Egger's test did not show a significant publication bias.
The yield of EUS is comparatively higher for the diagnosis of a pancreatic malignancy in patients with suspected cancer, but a non-diagnostic MDCT. Importantly, the majority of the lesions missed on CT represent PDAC, in which early diagnosis is essential.
胰腺导管腺癌(PDAC)的预后较差,部分原因是诊断延迟。即使在横断面成像方面取得了进展,小的胰腺恶性肿瘤也可能被遗漏。我们旨在确定在多排 CT 扫描(MDCT)未见明显肿块但临床怀疑胰腺恶性肿瘤的情况下,内镜超声(EUS)的表现。
系统地检索了多个数据库,以确定在临床怀疑胰腺恶性肿瘤但 MDCT 胰腺方案阴性或不确定的情况下评估 EUS 对胰腺恶性肿瘤检测的诊断性能的研究。共有四项研究符合纳入标准。使用森林图比较每个研究的点估计值与汇总敏感性和特异性的汇总估计值。使用漏斗图和 Egger 检验评估可能存在的发表偏倚。
所有研究均进行了 EUS 引导下细针抽吸。对 206 例临床怀疑胰腺肿块但 MDCT 不确定的患者进行了 EUS 检查。70%(n=144)的患者发现胰腺肿块(平均大小 21±1.2mm),42.2%(n=87)被诊断为 PDAC。在 MDCT 不确定的情况下,EUS 诊断胰腺恶性肿瘤的汇总估计值为敏感性 85%(95%CI 69-94%),特异性 58%(95%CI 40-74%),阳性预测值 77%(69-84%),阴性预测值 66%(95%CI 53-77%),准确率为 75%(95%CI 67-82%)。总结 ROC 曲线下面积为 0.80(95%CI 0.52-0.89)。漏斗图和 Egger 检验未显示出显著的发表偏倚。
在可疑癌症但 MDCT 无诊断的患者中,EUS 对胰腺恶性肿瘤的诊断率相对较高。重要的是,CT 上遗漏的大多数病变代表 PDAC,早期诊断至关重要。